Similarly, treatment with ruxolitinib or tofacitinib has, in most, cases led to improvement in neurological symptoms while alleviating systemic features such as chilblains, stroke, lung disease, and renal disease (Cattalini et al. 2021; Kuang et al. 2022; Li et al. 2022; Tüngler et al. 2016; Kothur et al. 2018; Mura et al. 2021; Pararajasingam et al. 2022; Wang et al. 2023; Sorokina, Raupov, and Kostik 2023; Zhang et al. 2021; Zheng et al. 2020) and markedly reducing IFN gene expression (Cattalini et al. 2021; Tüngler et al. 2016; Mura et al. 2021). This evidence concerns the gene IFNA1 and kidney disorder.